SEP
RMD icon

Signature Equity Partners’s ResMed RMD Stock Holding History

Signature Equity Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75K Sell
19
-1
-5% -$207 ﹤0.01% 1049
2026
Q1 		$4.53K Hold
20
– – ﹤0.01% 985
2025
Q4 		$4.86K Buy
+20
New +$5.12K ﹤0.01% 989

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Signature Equity Partners's RMD Position: Q2 2026 in Review

Signature Equity Partners reduced its ResMed (RMD) stake by 5% in Q2 2026, selling an estimated $207 and leaving 19 shares worth $3.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

Signature Equity Partners first reported a position in RMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.86K in Q4 2025. 891 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Signature Equity Partners held 19 shares of ResMed worth $3.75K as of Q2 2026.
  • Signature Equity Partners sold 1 ResMed share in Q2 2026, an estimated $207.
  • ResMed made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1049 holding.
  • Signature Equity Partners first reported a position in ResMed in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's ResMed position peaked at $4.86K in Q4 2025.
  • 891 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.